Genmab CEO says lower operating costs are a fleeting phenomenon

Genmab has revised its 2021 forecast for operating expenses, which includes research and development costs. Though whatever has been saved goes straight to next year, says the company's president and CEO, who points to Covid-19 as the cause for spending delays.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL PEDERSEN

Before Wedneday's quarterly report from Genmab was released, the biotech company had already upgraded its 2021 financial guidance for revenue and operating result.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading